Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests

In breve · dalla fonte (EU-Startups)

Di cosa si tratta

Switchpoint Bio, a Helsinki- and Cambridge, Massachusetts-based TechBio startup, has raised €4.75 million ($5.3 million) in pre-Seed financing to advance a blood-based epigenomic platform that gives drug developers a scalable view of how disease and treatment change human biology. The round includes a €4.48 million ($5 million) investment from Treehouse Delmar Investments. The company emerged […] The post Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests appeared first on EU-Startups .

Anteprima pubblicata dalla testata nel proprio feed. DuoBiz non ripubblica l'articolo né le immagini: per il testo completo, i dati e le dichiarazioni vai alla fonte.